stability guidance -draft
...Historically, all changes in drug product formulation were grouped together and required.....include results from microbial challenge studies performed on the drug product at.....throughout its expiration dating period, stability studies should include the drug product..
http://www.fda.gov/cder/guidance/1707dft.pdf (score=100)

MDI and DPI Drug Products
...The guidance sets forth information that should be provided to ensure continuing drug.....an internal reservoir containing sufficient formulation for multiple doses that are.....conduct and/or complete prescribed studies on production batches of a drug after approval..
http://www.fda.gov/cder/guidance/2180dft.pdf (score=87)

Q1A Stability Testing of New Drug Substances and Products
...Any available studies carried out on the drug product outside its immediate container or in other packaging materials can.....The primary batches should be of the same formulation and packaged in the same container.....Production batches of a drug substance or drug product for which the stability studies are initiated or completed..
http://www.fda.gov/cder/guidance/4282fnl.htm (score=67)

þÿ
...A batch of a drug substance or drug product used in a formal stability study,from which stability data are.....Data from these studies, in addition to long-term stability studies,can be used to assess longer term chemical effects at.....The primary batches should be of the same formulation and packaged in the same..container..
http://www.fda.gov/cder/guidance/5635fnl.pdf (score=67)

ICH Guidance for Industry Q1A(R2) Stability Testing of New Drug Substances...
...A batch of a drug substance or drug product used in a formal stability study, from which stability data are.....Data from these studies, in addition to long-term stability studies, can be used to assess longer term chemical effects at.....substance, and experience gained from clinical formulation studies. The likely changes on..
http://www.fda.gov/cber/gdlns/ichstab.pdf (score=67)

...Any available studies carried out on the drug product outside its immediate container or in other packaging materials can.....The primary batches should be of the same formulation and packaged in the same container.....Production batches of a drug substance or drug product for which the stability studies are initiated or completed..
http://www.fda.gov/cder/guidance/5635fnl.doc (score=67)

Q1B Photostability Testing of New Drug Substances and Products
...The extent of drug product testing should be established by assessing whether or not acceptable.....These studies are used to identify precautionary measures needed in manufacturing or.....Testing should progress until the results demonstrate that the drug product is adequately..
http://www.fda.gov/cder/guidance/1318.htm (score=43)

...The drug product's formulation provides consistent pharmacokinetic performance between individual dosage.....As part of INDs and NDAs for orally administered drug products, BA studies focus on determining the process.....In each comparison, the new formulation or new method of manufacture is the test product and the prior..
http://www.fda.gov/cder/guidance/5356fnl.doc (score=43)

Recommendations for Complying With the Pediatric Rule (21 CFR 314.55(a) and...
...In some cases, pediatric studies of a drug or biological product for life-threatening diseases may begin as early as phase.....FDA can waive the requirement for pediatric studies in age groups requiring a pediatric formulation if the manufacturer provides.....Where possible, an estimate of patient exposure to the drug product, with special reference to..
http://www.fda.gov/cder/guidance/3578dft.htm (score=43)

...In some cases, pediatric studies of a drug or biological product for life-threatening diseases may begin as early as phase.....FDA can waive the requirement for pediatric studies in age groups requiring a pediatric formulation if the manufacturer provides.....Where possible, an estimate of patient exposure to the drug product, with special reference to..
http://www.fda.gov/cder/guidance/3578dft.doc (score=42)

Guidance for Industry Botanical Drug Products
...These regulations require documentation of the drug substance, drug product, placebo, labeling, and an.....E provide information on the design of initial clinical trials for nonmarketed botanical drug products and for expanded.....Therefore, when feasible, active constituents should be identified during phase 3 studies. A single..
http://www.fda.gov/cder/guidance/4592fnl.htm (score=42)

/a/content.30891
...slight changes in the formulation on product variability, 19.. because they may have made it the same way.....to conduct and analyze renal studies, hepatic studies, 13.. population PK, and in all those guidances, we.....rate and extent of drug absorption, its pharmacokinetics, 16.. pharmacodynamics, and the..
http://www.fda.gov/ohrms/dockets/ac/00/transcripts/3657t2.pdf (score=40)

...For initial clinical studies on a botanical drug product that is not currently lawfully marketed in the United States.....The formulation/dosage form of the botanical product used in the proposed phase 3 study.....As with synthetic and/or highly purified drugs, pharmaceutical and biopharmaceutics studies for botanical drug..
http://www.fda.gov/cder/guidance/4592fnl.doc (score=38)

FR Doc 03-14140
...Any drug product labeled, represented, or promoted for use as an OTC antiperspirant drug that.....An average of 43 subjects completed the 1-week studies and returned their product to the.....Subjects applied the antiperspirant test formulation to one axilla and used either a..
http://www.fda.gov/OHRMS/DOCKETS/98fr/03-14140.htm (score=37)

Document
...as safe and effective and not misbranded active ingredients in OTC drug products document.....Even minor variations in formulation, effectiveness. formula is stated as: such as the.....The studies included antiperspirant-treated axilla to rate of ..in sweat production..
http://www.fda.gov/OHRMS/DOCKETS/98fr/03-14140.pdf (score=37)

...When a novel or non-novel but non-compendial excipient is included in the formulation of the drug product.....Parallel studies Studies of a parallel design can be used to demonstrate efficacy of a PEP, such.....Drug Product Specifications for the drug product should include tests for identity, biological activity of different classes of..
http://www.fda.gov/OHRMS/DOCKETS/98fr/2003d-0206-gdl0001.doc (score=37)

Frequently Asked Questions on Pediatric Exclusivity, etc.
...Under the rule, FDA has the authority to require pediatric studies on a drug product for the product's.....For example, if a firm markets an oral formulation, a topical cream, and an ophthalmic.....If an NDA for the drug product exists, the Written Request should be issued to the applicant of..
http://www.fda.gov/cder/pediatric/faqs.htm (score=36)

þÿ
...compendial excipient is included in the formulation of the drug product, manufacturing and.....disease, the efficacy studies in the NDA should include clinical studies in pediatric.....For a pancrelipase or pancreatin product to be approved as an ANDA, the proposed drug..
http://www.fda.gov/OHRMS/DOCKETS/98fr/2003d-0206-gdl0001.pdf (score=34)

Pediatric Rule
...In the development of a new drug or biological product, decisions about appropriate populations to study and.....younger pediatric populations cannot take the adult formulation, may also deny pediatric.....this age group with caution and would, whenever appropriate, permit such studies to occur..
http://www.fda.gov/cder/guidance/pedrule.pdf (score=33)

Safety and Effectiveness of New Drugs & Biological Products in Pediatric...
...The applicant may be required to develop a pediatric formulation for a drug product that is indicated for a very.....Although the preamble to the 1994 rule recognizes FDA's authority to require drug manufacturers to conduct pediatric studies on a.....FDA has tentatively concluded that it would be reasonable to expect a manufacturer of a product to produce a pediatric..
http://www.fda.gov/cder/guidance/pedrule.htm (score=32)

Las Vegas Injury Lawyer